Vertex Pharmaceuticals (VRTX) Long-Term Investments (2016 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Long-Term Investments of $5.7 billion for Q1 2026, up 11.51% year-over-year from $5.2 billion in Q1 2025, and up 0.66% quarter-over-quarter from $5.7 billion in Q4 2025.
Vertex Pharmaceuticals (VRTX) Long-Term Investments (2016 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Long-Term Investments history runs 7 years deep, the most recent figure standing at $5.7 billion for Q1 2026.
- In Q1 2026, Long-Term Investments rose 11.51% year-over-year to $5.7 billion; the TTM figure through Mar 2026 stood at $5.7 billion (up 11.51% YoY), while the FY2025 annual figure was $5.7 billion, up 11.83% from the prior year.
- Long-Term Investments for Q1 2026 stood at $5.7 billion, up from $5.7 billion in the prior quarter.
- The five-year high for Long-Term Investments was $5.7 billion in Q1 2026, with the low at $112.2 million in Q4 2022.
- The 5-year median for Long-Term Investments is $4.5 billion (2024), against an average of $3.8 billion.
- The sharpest annual moves came in 2023 and 2026: Long-Term Investments soared 2126.2% in 2023, then advanced 11.51% in 2026.
- Vertex Pharmaceuticals' Long-Term Investments stood at $112.2 million in 2022, then jumped by 2126.2% to $2.5 billion in 2023, then surged by 104.5% to $5.1 billion in 2024, then increased by 11.83% to $5.7 billion in 2025, then rose by 0.66% to $5.7 billion in 2026.
- Business Quant data shows VRTX's Long-Term Investments at $5.7 billion in Q1 2026, $5.7 billion in Q4 2025, and $5.7 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.79 Bn |
| Mar 31, 2026 | 5.75 Bn |
| Dec 31, 2025 | 5.71 Bn |
| Sep 30, 2025 | 5.72 Bn |
| Jun 30, 2025 | 5.65 Bn |
| Mar 31, 2025 | 5.16 Bn |
| Dec 31, 2024 | 5.11 Bn |
| Sep 30, 2024 | 4.70 Bn |
| Jun 30, 2024 | 4.39 Bn |
| Mar 31, 2024 | 4.38 Bn |
| Dec 31, 2023 | 2.50 Bn |
| Sep 30, 2023 | 1.70 Bn |
| Jun 30, 2023 | 1.36 Bn |
| Mar 31, 2023 | 1.08 Bn |
| Dec 31, 2022 | 112.20 Mn |
| Dec 31, 2017 | 20.45 Mn |
| Sep 30, 2017 | 20.45 Mn |
| Jun 30, 2017 | 20.25 Mn |
| Mar 31, 2017 | 20.28 Mn |
| Dec 31, 2016 | 20.28 Mn |